Multicentre Non-interventional Retrospective Cohort Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection

The study purpose was to assess the outcomes of therapy with olokizumab within complex therapy of Coronavirus disease 2019 (COVID-19) in hospitalised patients in real clinical practice setting. The study investigated patients' characteristics, disease progression, and efficacy and safety of olokizumab therapy.

开始日期2021-07-14

申办/合作机构

R-Pharm JSC

[+2]

NCT05187793 / Active, not recruiting临床3期

A Multicenter, Open-label, Randomized Study of the Efficacy and Safety of Artlegia (INN: Olokizumab) New Dosing Regimen in Patients With Coronavirus Infection (COVID-19) With Signs of Hyperinflammation

The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation.
This study is a multicentre, open-label, randomized, comparative, parallel group, active-controlled clinical trial.

开始日期2021-07-08

申办/合作机构

R-Pharm JSC

NCT04246762 / Completed临床1期

A Phase 1, Open-label, Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19, and CYP3A4

Olokizumab (OKZ) has been shown to reverse the inhibitory effect of IL-6 on the activity of Cytochrome P450 (CYP450) isozymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4/5 in vitro.
The goal of the study is to assess the effect of OKZ on the pharmacokinetics (PK) of the CYP450 probe substrates, caffeine (CYP1A2), S-warfarin (CYP2C9), omeprazole (CYP2C19), and midazolam (CYP3A4) in subjects with rheumatoid arthritis (RA).

开始日期2021-04-06

申办/合作机构

R-Pharm International, LLC

[+2]

100 项与 Olokizumab 相关的临床结果

登录后查看更多信息

100 项与 Olokizumab 相关的专利（医药）

登录后查看更多信息

项与 Olokizumab 相关的文献（医药）

2023-06-02·Zeitschrift fur Rheumatologie

Comparison of the efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials.

Article

作者: Young Ho Lee ; Gwan Gyu Song

OBJECTIVE:

This study aimed to assess the relative efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis (RA).

METHODS:

We performed a Bayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) to examine the efficacy and safety of olokizumab administered intravenously to RA patients at 64 mg/kg every 2 or 4 weeks (Q2 or Q4W).

RESULTS:

Five RCTs comprising 2609 patients met the inclusion criteria. Both olokizumab Q2 and Q4W treatments achieved a significant American College of Rheumatology 20% response (ACR20) compared with the placebo (odds ratio [OR] 3.21, 95% credible interval [CrI] 2.53-4.09; OR 3.05, 95% CrI 2.43-3.86). However, olokizumab Q2W was associated with the most favorable surface using the cumulative ranking curve (SUCRA) for the ACR20 response rate. The ranking probability based on the SUCRA indicated that olokizumab Q2W had the highest probability of being considered the best treatment option for achieving the ACR20 response rate, followed by olokizumab Q4W, adalimumab, and placebo. The ACR50 and 70 response rates showed a similar distribution pattern to the ACR20 response rate, except that olokizumab Q4W had a higher-ranking probability than olokizumab Q2W for ACR50. The SUCRA rating likelihood of adverse events (AEs) and withdrawal due to AEs showed that a placebo was likely to be the best intervention.

CONCLUSION:

Both olokizumab Q2 and Q4W were efficacious and well-tolerated treatments for active RA.

2023-06-01·The Cochrane database of systematic reviews

Interleukin-6 blocking agents for treating COVID-19: a living systematic review.

Review

作者: Lina Ghosn ; Rouba Assi ; Theodoros Evrenoglou ; Brian S Buckley ; Nicholas Henschke ; Katrin Probyn ; Carolina Riveros ; Mauricia Davidson ; Carolina Graña ; Hillary Bonnet ; Alexander Jarde ; Camila Ávila ; Camilla Hansen Nejstgaard ; Sonia Menon ; Gabriel Ferrand ; Philipp Kapp ; Claudia Breuer ; Christine Schmucker ; Yanina Sguassero ; Thu Van Nguyen ; Declan Devane ; Joerg J Meerpohl ; Gabriel Rada ; Asbjørn Hróbjartsson ; Giacomo Grasselli ; David Tovey ; Philippe Ravaud ; Anna Chaimani ; Isabelle Boutron

BACKGROUND:

It has been reported that people with COVID-19 and pre-existing autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm responsible for severe respiratory symptoms. Since interleukin 6 (IL-6) is one of the cytokines released during this inflammatory process, IL-6 blocking agents have been used for treating people with severe COVID-19.

OBJECTIVES:

To update the evidence on the effectiveness and safety of IL-6 blocking agents compared to standard care alone or to a placebo for people with COVID-19.

SEARCH METHODS:

We searched the World Health Organization (WHO) International Clinical Trials Registry Platform, the Living OVerview of Evidence (L·OVE) platform, and the Cochrane COVID-19 Study Register to identify studies on 7 June 2022.

SELECTION CRITERIA:

We included randomized controlled trials (RCTs) evaluating IL-6 blocking agents compared to standard care alone or to placebo for people with COVID-19, regardless of disease severity.

DATA COLLECTION AND ANALYSIS:

Pairs of researchers independently conducted study selection, extracted data and assessed risk of bias. We assessed the certainty of evidence using the GRADE approach for all critical and important outcomes. In this update we amended our protocol to update the methods used for grading evidence by establishing minimal important differences for the critical outcomes.

MAIN RESULTS:

This update includes 22 additional trials, for a total of 32 trials including 12,160 randomized participants all hospitalized for COVID-19 disease. We identified a further 17 registered RCTs evaluating IL-6 blocking agents without results available as of 7 June 2022. The mean age range varied from 56 to 75 years; 66.2% (8051/12,160) of enrolled participants were men. One-third (11/32) of included trials were placebo-controlled. Twenty-two were published in peer-reviewed journals, three were reported as preprints, two trials had results posted only on registries, and results from five trials were retrieved from another meta-analysis. Eight were funded by pharmaceutical companies. Twenty-six included studies were multicenter trials; four were multinational and 22 took place in single countries. Recruitment of participants occurred between February 2020 and June 2021, with a mean enrollment duration of 21 weeks (range 1 to 54 weeks). Nineteen trials (60%) had a follow-up of 60 days or more. Disease severity ranged from mild to critical disease. The proportion of participants who were intubated at study inclusion also varied from 5% to 95%. Only six trials reported vaccination status; there were no vaccinated participants included in these trials, and 17 trials were conducted before vaccination was rolled out. We assessed a total of six treatments, each compared to placebo or standard care. Twenty trials assessed tocilizumab, nine assessed sarilumab, and two assessed clazakizumab. Only one trial was included for each of the other IL-6 blocking agents (siltuximab, olokizumab, and levilimab). Two trials assessed more than one treatment. Efficacy and safety of tocilizumab and sarilumab compared to standard care or placebo for treating COVID-19 At day (D) 28, tocilizumab and sarilumab probably result in little or no increase in clinical improvement (tocilizumab: risk ratio (RR) 1.05, 95% confidence interval (CI) 1.00 to 1.11; 15 RCTs, 6116 participants; moderate-certainty evidence; sarilumab: RR 0.99, 95% CI 0.94 to 1.05; 7 RCTs, 2425 participants; moderate-certainty evidence). For clinical improvement at ≥ D60, the certainty of evidence is very low for both tocilizumab (RR 1.10, 95% CI 0.81 to 1.48; 1 RCT, 97 participants; very low-certainty evidence) and sarilumab (RR 1.22, 95% CI 0.91 to 1.63; 2 RCTs, 239 participants; very low-certainty evidence). The effect of tocilizumab on the proportion of participants with a WHO Clinical Progression Score (WHO-CPS) of level 7 or above remains uncertain at D28 (RR 0.90, 95% CI 0.72 to 1.12; 13 RCTs, 2117 participants; low-certainty evidence) and that for sarilumab very uncertain (RR 1.10, 95% CI 0.90 to 1.33; 5 RCTs, 886 participants; very low-certainty evidence). Tocilizumab reduces all cause-mortality at D28 compared to standard care/placebo (RR 0.88, 95% CI 0.81 to 0.94; 18 RCTs, 7428 participants; high-certainty evidence). The evidence about the effect of sarilumab on this outcome is very uncertain (RR 1.06, 95% CI 0.86 to 1.30; 9 RCTs, 3305 participants; very low-certainty evidence). The evidence is uncertain for all cause-mortality at ≥ D60 for tocilizumab (RR 0.91, 95% CI 0.80 to 1.04; 9 RCTs, 2775 participants; low-certainty evidence) and very uncertain for sarilumab (RR 0.95, 95% CI 0.84 to 1.07; 6 RCTs, 3379 participants; very low-certainty evidence). Tocilizumab probably results in little to no difference in the risk of adverse events (RR 1.03, 95% CI 0.95 to 1.12; 9 RCTs, 1811 participants; moderate-certainty evidence). The evidence about adverse events for sarilumab is uncertain (RR 1.12, 95% CI 0.97 to 1.28; 4 RCT, 860 participants; low-certainty evidence). The evidence about serious adverse events is very uncertain for tocilizumab (RR 0.93, 95% CI 0.81 to 1.07; 16 RCTs; 2974 participants; very low-certainty evidence) and uncertain for sarilumab (RR 1.09, 95% CI 0.97 to 1.21; 6 RCTs; 2936 participants; low-certainty evidence). Efficacy and safety of clazakizumab, olokizumab, siltuximab and levilimab compared to standard care or placebo for treating COVID-19 The evidence about the effects of clazakizumab, olokizumab, siltuximab, and levilimab comes from only one or two studies for each blocking agent, and is uncertain or very uncertain.

AUTHORS' CONCLUSIONS:

In hospitalized people with COVID-19, results show a beneficial effect of tocilizumab on all-cause mortality in the short term and probably little or no difference in the risk of adverse events compared to standard care alone or placebo. Nevertheless, both tocilizumab and sarilumab probably result in little or no increase in clinical improvement at D28. Evidence for an effect of sarilumab and the other IL-6 blocking agents on critical outcomes is uncertain or very uncertain. Most of the trials included in our review were done before the waves of different variants of concern and before vaccination was rolled out on a large scale. An additional 17 RCTs of IL-6 blocking agents are currently registered with no results yet reported. The number of pending studies and the number of participants planned is low. Consequently, we will not publish further updates of this review.

2023-03-30·Journal of biomolecular structure & dynamics

Targeting Olokizumab-Interleukin 6 interaction interface to discover novel IL-6 inhibitors.

Article

作者: Que-Huong Tran ; Hoang-Nhi Cao ; Dac-Nhan Nguyen ; Thi-Thuy-Nga Tran ; Minh-Tri Le ; Quoc-Thai Nguyen ; Van-Thanh Tran ; Viet-Hung Tran ; Khac-Minh Thai

The IL-6/IL-6R or IL-6/GP130 protein-protein interactions play a significant role in controlling the development of chronic inflammatory diseases, such as rheumatoid arthritis, Castleman disease, psoriasis, and, most recently, COVID-19. Modulating or antagonizing protein-protein interactions of IL6 binding to its receptors by oral drugs promises similar efficacy to biological therapy in patients, namely monoclonal antibodies. In this study, we used a crystal structure of the Fab part of olokizumab in a complex with IL-6 (PDB ID: 4CNI) to uncover starting points for small molecule IL-6 antagonist discovery. Firstly, a structure‑based pharmacophore model of the protein active site cavity was generated to identify possible candidates, followed by virtual screening with a significant database Drugbank. After the docking protocol validation, a virtual screening by molecular docking was carried out and a total of 11 top hits were reported. Detailed analysis of the best scoring molecules was performed with ADME/T analysis and molecular dynamics simulation. Furthermore, the Molecular Mechanics-Generalized Born Surface Area (MM/GBSA) technique has been utilized to evaluate the free binding energy. Based on the finding, one newly obtained compound in this study, namely DB15187, may serve as a lead compound for the discovery of IL-6 inhibitors.Communicated by Ramaswamy H. Sarma.

项与 Olokizumab 相关的新闻（医药）

2023-07-27

·药融圈

不断收购、剥离：比利时制药巨头UCB，在纯粹与专注中发展壮大

▲8月03-04日 CMC-China大会 · 限时免费扫码报名中注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。从药融云数据www.pharnexcloud.com获悉，2023年6月7日，全球生物制药公司UCB Pharma宣布，欧盟委员会(EC)已授予BIMZELX(bimekizumab)上市许可，用于治疗患有活动性银屑病关节炎（PsA）和患有活动性轴向脊柱关节炎（axSpA）的成人患者。欧盟的这些批准代表了bimekizumab在PsA和axSpA中的首次上市许可，也是bimekizumab继2021年8月获批用于治疗中度至重度斑块状银屑病后在欧盟的第二和第三个适应症。UCB也再一次证明了老牌企业的实力不容小觑。药融云数据www.pharnexcloud.com；药品信息从工业化学品到生物制药公司UCB（优时比）是一家总部位于比利时的生物制药公司，由比利时商人Emmanuel Janssen于1928年在布鲁塞尔创立，最初专注于工业化学品；20世纪30年代扩张进入美国市场；20世纪50年代取得了第一个突破性治疗，随后在20世纪60年代对生物技术领域进行了深入研究；20世纪80年代，UCB注册的Zyrtec（一种新型抗组胺药产品）取得了重大突破；20世纪90年代推出Keppra，进一步刺激了全球增长。21世纪初，UCB开始转型为一家纯粹的生物制药公司，重要的里程碑包括2004年收购英国生物技术公司Celltech和2006年收购德国制药公司Schwarz Pharma。收购Celltech相关报道收购Schwarz使UCB能够推出两种针对CNS疾病的新药：Neupro（rotigotine）和Vimpat（拉考沙胺），Neupro（rotigotine）是一种用于治疗帕金森病的透皮贴剂，Vimpat (lacosamide)是一种抗惊厥药。收购Schwarz相关报道2008年，UCB与Beryllium建立了多年的合作关系，Beryllium是免疫和中枢神经系统疾病治疗的开发商。到2014年，UCB收购了该公司的少数股权；2015年，UCB将其在印度和南亚的品牌仿制药业务出售给Dr. Reddy's Laboratories；2020年4月，优时比宣布已完成对免疫系统疾病专家Ra Pharma的收购；2022年1月，UCB宣布以19亿美元收购Zogenix，2022年3月，UCB宣布已完成对其收购。当前UCB正继续努力解决免疫学和神经学未满足的需求，公司建立了三个研究平台：新化学实体（小分子和肽）、新生物实体（单克隆抗体）和先进治疗药物（ATMP）。通过评估药物之外的解决方案，并在早期研究中通过数据和人工智能扩展到设备或数字健康解决方案，UCB的目标是通过在研究和早期开发的各个方面进行持续创新，确保最佳的个体患者体验。在全球范围内，UCB已建立了三个战略研究中心（比利时、英国和美国），四个制造站点（比利时、中国、日本、瑞士）以及八个研发站点，相信在技术平台以及数据共享的基础上，UCB必将在未来为所有需要其药物的患者带来所得。做“纯粹”的专家作为比利时数一数二的制药企业，在进行一系列收购以及剥离非核心业务之后，UCB主要专注于神经系统领域和免疫学领域的药物研发，除此之外，UCB还是一个合格的疾病宣传者，直接体现了欧洲老牌企业的人文关怀。在中枢神经系统疾病领域，公司专注于癫痫、糖尿病神经性疼痛、多发性硬化症、纤维肌痛症、不宁腿综合征和帕金森娜氏病，免疫学领域主要研究过敏、骨质疏松症、克罗那氏病、类风湿关节炎和系统性红斑狼疮等。一神经系统领域产品神经领域产品1 癫痫癫痫发作主要分为局灶性癫痫发作和全身性癫痫发作。局灶性癫痫发作仅从大脑的一个部位开始，全身性癫痫发作是整个大脑同时异常活动的结果。当前已经确定了100多种不同的癫痫综合征。癫痫病因有五大类，包括：感染、结构性原因、遗传原因、自身免疫性癫痫和代谢原因。在开发过程中，UCB正在研究一种可能使癫痫发作快速终止的新型救援药物，并探索CDKL5缺乏症（一种罕见的发育性癫痫性脑病）的治疗方法。针对癫痫已获批药物的情况如下：● Briviact（布瓦西坦[brivaracetam]）在欧洲，Briviact（布瓦西坦）被用于辅助治疗成人、青少年和2岁以上癫痫儿童部分性癫痫发作伴或不伴继发性全身性发作的辅助治疗；在美国，Briviact（布瓦西坦）CV用于治疗1个月及以上患者的部分性癫痫发作。● Vimpat（拉考沙胺[lacosamide]）在欧盟，Vimpat（拉考沙胺）（薄膜包衣片剂、糖浆和输注溶液）被用于单药治疗成人、青少年和2岁以上癫痫儿童伴或不伴继发性全身性的部分性癫痫发作；在美国，Vimpat有口服片剂、口服溶液和注射剂两种形式，Vimpat（拉考沙胺）CV用于治疗1个月及以上患者的部分性癫痫发作、4岁及以上患者原发性全身强直阵挛发作的辅助治疗。● Keppra（左乙拉西坦[levetiracetam]）在欧洲，Keppra（左乙拉西坦）被用于治疗16岁以上新诊断癫痫成人和青少年的部分性癫痫发作伴或不伴继发性全身性发作；在美国，用于治疗1个月及以上患者的部分性癫痫发作、12岁及以上青少年肌阵挛性癫痫患者肌阵挛发作的辅助治疗、6岁及以上特发性全身性癫痫患者的原发性全身强直阵挛发作的辅助治疗。● Nayzilam（咪达唑仑[midazolam]）Nayzilam（咪达唑仑）是一种苯二氮卓类药物，在美国用于急性治疗间歇性、刻板的频繁癫痫发作活动（即癫痫发作群、急性重复性癫痫发作），这些发作不同于12岁及以上癫痫患者的常规癫痫发作模式。2 帕金森病帕金森病是第二常见的神经退行性疾病，随着疾病的进展，症状逐渐出现并慢慢恶化。每个帕金森氏症患者都有不同的症状，但最容易识别的症状与称为运动症状（如震颤）的运动有关。当产生多巴胺的脑细胞死亡或无法有效运作时，就会发生帕金森氏症。在欧洲，Neupro（罗替戈汀透皮贴剂）用于治疗早期特发性帕金森病的体征和症状，作为单一疗法（即无左旋多巴）或与左旋多巴联合使用；在美国，Neupro（罗替戈汀透皮系统）适用于治疗帕金森病。3 不宁腿综合征（RLS）不宁腿综合征（RLS），也称为威利斯-埃克博姆病（WED），是一种慢性神经系统疾病。它的特点是腿部无法控制。RLS的确切原因尚不清楚。有证据表明，当使用神经递质多巴胺的大脑通路中断时，就会发生RLS，这是产生平滑肌活动和运动所必需的。在欧洲，Neupro（罗替戈汀透皮贴剂）用于成人中度至重度特发性不宁腿综合征的对症治疗；在美国，Neupro（罗替戈汀透皮系统）用于治疗中度至重度原发性不宁腿综合征。4 Dravet综合征(DS) 和Lennox-Gastaut综合征(LGS)Dravet综合征是一种发育性和癫痫性脑病，超过80%被诊断患有Dravet综合征的人具有SCN1A基因突变，这种通常不是遗传的突变会影响离子通道在大脑中的运作方式，并非所有SCN1A突变都会导致Dravet综合征，Dravet综合征有时与其他基因突变有关。在欧盟和英国，Fintepla（芬氟拉明[fenfluramine]）用于治疗与Dravet综合征相关的癫痫发作，作为2岁及以上患者其他抗癫痫药物的附加疗法；在美国，Fintepla（芬氟拉明）用于治疗2岁及以上患者的Dravet综合征（DS）和Lennox-Gastaut综合征（LGS）相关癫痫发作。二免疫学领域产品免疫学领域产品1 Cimzia(塞妥珠单抗[certolizumab pegol])Cimzia（塞妥珠单抗）是一种肿瘤坏死因子（TNF）阻滞剂在美国用于治疗成人活动性强直性脊柱炎（AS）；减轻克罗恩病的体征和症状，并维持对常规治疗反应不足的中度至重度活动性疾病成人患者的临床反应；治疗适合全身治疗或光疗的中度至重度斑块型银屑病（PsO）成人患者；治疗活动性银屑病关节炎（PsA）成年患者；治疗成人中度至重度活动性类风湿关节炎（RA）。在欧洲用于治疗患有严重活动性轴向脊柱关节炎的成年患者；治疗适合全身治疗的成人中度至重度斑块状银屑病；用于与甲氨蝶呤（MTX）联合用于对包括甲氨蝶呤在内的疾病改善抗风湿药物（DMARDs）的反应不足的成人活动性银屑病关节炎；以及用于成人患者中度至重度活动性类风湿关节炎（RA）的治疗不足。在瑞士用于诱导临床反应以及对常规治疗反应不充分的活动性克罗恩病患者的临床反应和缓解维持。2 EVENITY（罗莫珠单抗[romosozumab]在欧洲，EVENITY（罗莫珠单抗）用于治疗骨折风险高的绝经后妇女的严重骨质疏松症。3 Bimzelx（比美吉珠单抗[bimekizumab]在欧盟和英国，Bimzelx（比美吉珠单抗）用于治疗适合全身治疗的成人中度至重度斑块状银屑病。在研管线到2022年，UCB完成了关键研究，启动了监管文件，并为管道增加了新的临床开发项目，截止2022年研发管道情况如下：研发管线（截止2022.12.31）1 rozanolixizumab（FcRn抑制剂）rozanolixizumab是一种SC给药的人源化单克隆抗体，具有高亲和力与人新生儿Fc受体（FcRn）特异性结合。它旨在阻断FcRn和免疫球蛋白G（IgG）的相互作用，加速抗体的分解代谢并降低致病性IgG自身抗体的浓度。药融云数据www.pharnexcloud.com针对MOG抗体病的研究目前进行到临床试验三期，预计2024年下半年得到三期顶线结果；针对自身免疫性脑炎和严重纤维肌痛综合征的研究目前均进行到临床试验二期，预计2024年上半年获得二期顶线结果2 fenfluramine（5-HT激动剂）fenfluramine是一种血清素释放剂，因此通过释放血清素刺激多种5-HT受体亚型。针对CDKL5缺乏症的研究目前进行到临床试验三期，预计2024年下半年得到三期顶线结果（在收购Zogenix后，UCB决定继续开发fenfluramine治疗CDKL5缺乏症或CDD的3期临床试验项目。CDD是一种罕见的发育性癫痫性脑病，由CDKL5基因突变引起，虽然很罕见，但CDD是最常见的遗传性癫痫形式之一）3 doxecitine/doxribtimine（MT1621，核苷治疗）针对TK2缺乏症的研究目前进行到临床试验三期，预计2024年上半年正式开始提交4 dapirolizumab pegol（抗CD40L抗体）与Biogen合作研发系统性红斑狼疮，目前进行到临床试验三期，预计2024年上半年获得顶线结果5 staccato alprazolam (benzodiazepine)针对典型的长时间癫痫发作研究，目前进行到临床试验三期，预计2024年上半年获得顶线结果6 bepranemab（抗tau蛋白抗体）bepranemab是一种重组、人源化、全长免疫球蛋白G4单克隆抗tau蛋白抗体，正在与Roche、Genentech合作用于阿尔兹海默症患者的研究，目前进行到临床试验二期，预计2024年第四季度获得顶线结果7 UCB0599（α-syn-错误折叠抑制剂）UCB0599是一种口服生物可利用和脑屏障渗透小分子，可防止核素的病理错误折叠和积累。核素是一种在帕金森病（PD）病理中起关键作用的蛋白质。通过抑制突触核蛋白错误折叠的致病生物学特性，人们认为PD的进展可以被减缓或停止。根据与诺华公司达成的全球联合开发和联合商业化协议，目前该项目进行到临床试验二期，预计2024年第四季度获得顶线结果8 UCB9741和UCB1381UCB启动了特应性皮炎的1b期研究，针对UCB9741和UCB1381的两种不同的靶向免疫途径。早期研究评估了中度至重度特应性皮炎患者的安全性、药代动力学和有效性。注：特应性皮炎是一种慢性疾病，会导致皮肤干燥、发痒和炎症，可影响所有年龄段的人。年报信息UCB 2022年收入达到55.17亿欧元，净销售额为51.4亿欧元。这归因于UCB产品组合的持续增长，即CIMZIA、BRIVIACT、NAYZILAM、EVENITY以及新推出的BIMZELX、FINTEPLA。这一表现被VIMPAT在美国和欧洲以及KEPPRA在日本失去排他性的影响所抵消。特许权使用费收入和费用为8500万欧元，其他收入2.92亿欧元，增长了28%，这归因于研发合作伙伴的里程碑和其他付款，其中包括来自知识产权销售（olokizumab）的一次性7000万欧元。 2022年营收报告2022年运营费用增加到31.68亿欧元，反映了由于Zogenix的加入和整合而产生的费用增加。运营费用包括：营销和销售费用为14.89亿欧元，研发费用16.7亿欧元以及2.25亿欧元的一般和管理费用，其他营业收入为2.16亿欧元。基本运营盈利能力（调整后的EBITDA）达到12.6亿欧元，反映了由于失去排他性和Zogenix的整合而导致的收入下降，这解释了总运营费用的增加。营销和销售费用反映了正在进行的和即将推出的投资，研发费用反映了管道的进展。其他营业收入的增长是由EVENITY推动的。2022年利润下降至4.18亿欧元。核心每股收益为4.37欧元，而2021年为6.49欧元。对于比利时这样经济高度对外依赖的国家，外贸可以说是整个国家的经济命脉，如今美国和欧洲仍然是UCB的主要市场，但是UCB貌似也在对中国的战略布局进行调整。从20世纪晚期进入中国，UCB有一段高速发展的时期，随着专利到期以及集采风波，UCB貌似不再像之前一样“顺风顺水”，公司的药物接连遭遇滑铁卢，当前UCB正在不断创新并努力寻找新的方法，公司坚持每年投入资金的30%进行药物研发，专注于神经系统和免疫学领域的研究，相信UCB会在自己选择的领域走得更远。一最新获批资讯2023年6月23日，UCB宣布FDA批准RYSTIGGO（罗扎诺利珠单抗[rozanolixizumab-noli]）用于治疗抗乙酰胆碱受体（AchR）或抗肌肉特异性酪氨酸激酶（MuSK）抗体阳性的成年全身性重症肌无力（gMG）患者。并将于2023年第三季度在美国上市。（在美国以外，罗扎诺利珠单抗未被全球任何其他监管机构批准用于任何适应症）图文：获批新闻报道此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场参考：NMPA/CDE；药融云数据www.pharnexcloud.com；FDA/EMA/PMDA；相关公司公开披露（除标注外，正文图片均来自企业官网）；https://www.ucb.com/；https://www.ucbchina.com/；https://mp.weixin.qq.com/s/IG8TS6vIfOJvdDh2J2mTeA；https://mp.weixin.qq.com/s/Kl3PcxagYv4M1-qXEQnKfw；https://mp.weixin.qq.com/s/oxA0I5y62Q5VULbbqexJgQ；等等。关于CMC-China 博览会融合产业力量，重构行业未来！本次CMC-China博览会汇聚300+医药及上下游全产业链的企业积极报名参展，数千名专业观众报名参观，展会现场将举办15场专业论坛。充分体现了“医药人办医药展，专业人办专业展”的理念。了解更多：一文看最全议程！8月3-4日：2023第五届中国国际生物&化学制药博览会点分享点点赞点在看

并购突破性疗法

2023-01-09

·PRNewswire

Rheumatoid Arthritis Market is Expected to Showcase Significant Growth in the 7MM at a Minimal CAGR of 1.9% During the Study Period (2019-2032), Predicts DelveInsight

The dynamics of the rheumatoid arthritis market are anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in the R&D activities. Companies like GlaxoSmithKline [Otilimab (MOR103/GSK3196165)], Taisho Pharmaceutical [Ozoralizumab (TS-152)], Aclaris Therapeutics [Zunsemetinib (ATI-450)], Abivax [ABX464], and others with their key candidates are in the late clinical and filing stage. LAS VEGAS, Jan. 9, 2023 /PRNewswire/ -- DelveInsight's Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the 7MM [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Rheumatoid Arthritis Market Report As per DelveInsight analysis, the rheumatoid arthritis market size in the 7MM was approximately USD 27 billion in 2021. According to the assessment done by DelveInsight, the estimated total rheumatoid arthritis prevalent population in the 7MM was approximately 4. 7 million in 2021. Leading rheumatoid arthritis companies such as Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol Myers Squibb, Oscotec/Genosco, Mesoblast, Pfizer Akros Pharma/Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, SynAct Pharma, Cyxone, and others are developing novel rheumatoid arthritis drugs that can be available in the rheumatoid arthritis market in the coming years. The promising rheumatoid arthritis therapies in the pipeline include Ozoralizumab (TS-152), Artlegia (Olokizumab), Otilimab (GSK3196165/MOR103), Zunsemetinib (ATI-450), Ritlecitinib (PF-06651600), ABX464, Branebrutinib, Cevidoplenib (SKI-O-703), MPC-300-IV, PF-06650833, JTE -051, ABBV-154, TAS5315, MBS2320, AMT-101, AP1189, Rabeximod (Rob 803), and others. In June 2022, Cyxone received a response from a Type B Pre-IND meeting with the US FDA. The response from the FDA facilitates Cyxone to continue planning the Phase IIb study with Rabeximod in RA. In December 2021, Taisho Pharmaceuticals presented the interim results from a 24-week administration in Phase II/III clinical trial (OHZORA study) of ozoralizumab in adult patients with RA at the annual meeting of the Japanese Society for Clinical Rheumatology and Related Research. Discover which therapies are expected to grab the major rheumatoid arthritis market share @ Rheumatoid Arthritis Market Report Rheumatoid Arthritis Overview Rheumatoid arthritis is a type of autoimmune disease. It happens when our immune system, which is supposed to defend us, malfunctions and starts attacking our own tissues. It causes inflammation in the joint lining (the synovium). As a result, joints may become red, warm, swollen, and painful, which are all symptoms of rheumatoid arthritis. The precise causes of rheumatoid arthritis are still unknown. Because the early signs and symptoms of rheumatoid arthritis are similar to those of many other diseases, it can be difficult to detect in its early stages. There is no single blood test or physical finding that can confirm the diagnosis of rheumatoid arthritis. There is no known cure for rheumatoid arthritis. However, clinical trials of rheumatoid arthritis show that remission of symptoms is more common when rheumatoid arthritis treatment with disease-modifying antirheumatic medicines begins early (DMARDs). Rheumatoid Arthritis Epidemiology Segmentation DelveInsight estimates that there were approximately 4.7 million prevalent cases of rheumatoid arthritis in the 7MM in 2021. Among the EU4 and the UK countries, Germany accounted for the highest number of rheumatoid arthritis cases, whereas France accounted for the lowest cases in 2021 The rheumatoid arthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalent Cases Total Diagnosed Prevalent Cases Gender-specific Prevalent Cases Age-specific Prevalent Cases Severity-specific Prevalent Cases Patients on Targeted Therapies Line-Wise Treated Cases Download the report to understand which factors are driving rheumatoid arthritis epidemiology trends @ Rheumatoid Arthritis Epidemiological Insights Rheumatoid Arthritis Treatment Market Over the last few years, there has been a dramatic improvement in rheumatoid arthritis outcomes as a direct result of paradigm shifts in rheumatoid arthritis treatment. At the moment, the main rheumatoid arthritis treatment options are Medicine (for long-term relief of symptoms and slowing the progression of the condition), Supportive treatments (including physiotherapy and occupational therapy, to help keep the patient mobile and manage any problems related to daily activities), and Surgery (to correct any joint problems that develop over a period of time). Nonsteroidal anti-inflammatory drugs (NSAIDs) are typically used only for symptomatic treatment until a rheumatoid arthritis diagnosis is established because they reduce pain and stiffness in patients but have no effect on disease progression. Moreover, disease-modifying antirheumatic drugs (DMARDs) are used to target inflammation and prevent further joint damage and disease progression. DMARDs are a class of drugs that have been shown to affect the underlying cause of rheumatoid arthritis by reducing immune system overactivity, thereby alleviating pain, swelling, and stiffness and preventing joint changes. DMARDs can be prescribed singly or in combination as an initial part of treatment. Methotrexate is the first-line DMARD agent for the majority of rheumatoid arthritis patients. It has a relatively quick onset of action at therapeutic doses (6-8 weeks), good efficacy, a low toxicity profile, is easy to administer, and is relatively inexpensive. To know more about rheumatoid arthritis guidelines, visit @ Rheumatoid Arthritis Management Rheumatoid Arthritis Pipeline Therapies and Key Companies Artlegia (Olokizumab): R-Pharm TS-152 (Ozoralizumab): Taisho Pharmaceuticals Otilimab (GSK3196165/MOR103): GlaxoSmithKline ATI-450 (Zunsemetinib/CDD-450): Aclaris Therapeutics Branebrutinib: Bristol Myers Squibb LY3462817: Eli Lilly and Company TAS5315: Taiho Pharmaceutical Rabeximod (Rob 803): Cyxone GS-5718: Gilead Sciences KPL-404: Kiniksa Pharmaceuticals MBS2320: Istesso AMT-101: Applied Molecular Transport Dazodalibep (HZN-4920): Horizon Therapeutics Cevidoplenib (SKI-O-703): Genosco/Oscotec HB-AdMSCs: Hope Biosciences ABX464: Abivax MPC-300-IV: Mesoblast PF-06650833: Pfizer JTE 051: Akros Pharma/Japan Tobacco Dekavil (F8IL10): Pfizer/Philogen ABBV-154: AbbVie PF-06651600 (Ritlecitinib): Pfizer AP1189: SynAct Pharma Learn more about the FDA-approved drugs for rheumatoid arthritis @ Drugs for Rheumatoid Arthritis Treatment Rheumatoid Arthritis Market Dynamics The dynamics of the rheumatoid arthritis market is anticipated to change in the future due to the increasing awareness and expected increase in investment in the R&D activities by the leading companies working in the rheumatoid arthritis market space. Moreover, current therapies, such as biological DMARDs, have shown promising results in treating rheumatoid arthritis patients, and market penetration is expected to increase in the future, driving rheumatoid arthritis market growth. Furthermore, there is still a high demand for therapies with a similar efficacy profile to current therapies but a better safety profile and a more patient-friendly RoA. Oral classes, such as JAKi and the upcoming BTKi, are expected to contribute to the rheumatoid arthritis market growth due to patient-friendly RoA. However, several factors are likely to hamper the rheumatoid arthritis market growth. The rheumatoid arthritis market is highly competitive, and new entrants are expected to face some resistance and low uptake because anti-TNFs currently dominate the rheumatoid arthritis market, and the entry of biosimilars will pose significant challenges to new and upcoming treatment options in the rheumatoid arthritis market. In addition, the entry of biosimilars has already begun in the US and EU (i.e., Remicade biosimilars), and as a result, sales value has started to decline. The impact will be more pronounced when biosimilars/ generics of some blockbuster drugs, such as Humira (i.e., 2023 in the US), Xeljanz (i.e., 2025 in the US), will enter the rheumatoid arthritis market, and this will significantly impact the growth of the rheumatoid arthritis market. Scope of the Rheumatoid Arthritis Market Report Therapeutic Assessment: Rheumatoid Arthritis current marketed and emerging therapies Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Rheumatoid Arthritis Market Access and Reimbursement Discover more about rheumatoid arthritis drugs in development @ Rheumatoid Arthritis Clinical Trials Table of Contents Related Reports Rheumatoid Arthritis Epidemiology Forecast Rheumatoid Arthritis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted rheumatoid arthritis epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Juvenile Rheumatoid Arthritis Pipeline Juvenile Rheumatoid Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products and the key juvenile rheumatoid arthritis companies, including Novartis, AbbVie, Eli Lilly and Company, Sanofi, among others. Juvenile Rheumatoid Arthritis Market Juvenile Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key juvenile rheumatoid arthritis companies, including Novartis, AbbVie, Eli Lilly and Company, Sanofi, among others. Psoriatic Arthritis Pipeline Psoriatic Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriatic arthritis companies, including Mylan, Celltrion, Pfizer, Amgen, among others. Psoriatic Arthritis Market Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriatic arthritis companies, including Mylan, Celltrion, Pfizer, Amgen, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market Related Healthcare Blogs Rheumatoid Arthritis Emerging Drugs Knee Osteoarthritis Pipeline Rheumatoid Arthritis Market Scenario Juvenile Idiopathic Arthritis Therapy Market Related Healthcare Services Healthcare Business Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

临床结果

2021-05-20

·BioSpace

Global Roundup: Russia-Developed RA Drug Shows Significant Promise in Phase III Study

Russia-based R-Pharm Group announced a new rheumatoid arthritis (RA) drug, olokizumab, has been found to offer significant benefits to patients. Findings from the Phase III CREDO study were presented at the British Society of Rheumatology Annual Conference. The results showed significant improvements to the signs and symptoms of RA patients compared to those in the placebo and methotrexate group, not only in biologically naïve patients, but also among the difficult to treat population with active RA inadequately controlled by TNF-α inhibitor therapy, the company announced. Olokizumab is a monoclonal antibody specific for the interleukin-6 (IL-6) cytokine. It targets the IL-6 ligand rather than the receptor, and selectively blocks the final assembly of the signaling complex, the company announced. Olokizumab is the first direct inhibitor of interleukin-6 (IL-6) authorized for commercial use for this indication. Treatment with olokizumab was well-tolerated and consistent with the established safety profile of anti-IL-6 agents, the company announced. In May 2020, olokizumab received a market authorization from Russia’s Ministry of Health under the trade name "Artlegia." R-Pharm is currently establishing GMP-certified olokizumab production at facilities in France and Germany to enable prompt approval of the drug in the American and European markets. Elsewhere around the globe: IcanoMAB – Germany-based IcanoMAB received positive regulatory advice for the clinical development path of its anti-IL-1R7 antibody in late-stage COVID-19. IcanoMAB has published the pre-clinical proof-of-concept for the anti-IL-1R7 antibody that blocks the signal transduction of the interleukin-18 (IL-18) receptor. Recently, the company secured positive regulatory advice for its clinical development plan in late-stage COVID-19. IcanoMAB is currently entering discussions with interested parties for a development partnership of its anti IL-1R7 antagonist antibody. Memo Therapeutics – Switzerland’s Memo Therapeutics announced its COVID-19 antibody MTX-COVAB has shown efficacy against both the original virus as well as the UK variant (B.1.1.7). Memo is now preparing MTX-COVAB for clinical evaluation. Using its microfluidic, single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery, Memo can discover novel antibodies at unprecedented speed, efficiency and sensitivity derived from recovered patient samples. This approach has enabled the company to also identify a very promising antibody candidate against the South African variant (B.1.351). Sphere Fluidics – U.K.-based Sphere Fluidics, which develops single cell analysis systems, announced it has enhanced the capability and performance of its Cyto-Mine System. The updated design provides improvements that will help streamline workflows, reduce costs, increase throughput, and enable high-value clones to be captured in a single run, the company said. Cyto-Mine is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. The new electronics design improves system performance, reliability, and stability, while the updated software features help to provide a better user experience, reduce user-instrument interaction, and allow for more robust data analysis. Holborn – Also based in the U.K., AI Solutions company Holborn will launch a dedicated business unit in India dubbed Holborn Wells India. Holborn said the launch is in response to an increasing need for “high-quality and cost-effective molecular In Vitro Diagnostics (IVD) in the country due to ongoing COVID-19 concerns.” Holborn Wells India will develop and deliver IVD products for infectious diseases by leveraging data and innovative diagnostic capabilities, with continued pressure on the nation’s health service as a result of the pandemic accelerating the need for operational capacity. Holborn Wells India already signed a deal with an Indian-based company to produce Holborn Wells’ IVD products in order to assist until a fully operational manufacturing location can be established. Milestone Pharmaceuticals – Canada’s Milestone Pharmaceuticals Inc. announced an exclusive license and collaboration with Shanghai-based Ji Xing Pharmaceuticals. The companies will develop and commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) and additional cardiovascular conditions in Greater China. Under terms of the deal, Milestone will receive an upfront cash payment consisting of $15 million and a $5 million equity investment. In addition, Milestone is eligible to receive up to $107.5 million in milestone payments and royalties on future sales of etripamil in Greater China. BioMed X – Germany’s BioMed X extended its collaboration agreement with Merck. Under terms of the new agreement, Merck will start up to six additional research projects at the BioMed X Institute, building on ongoing research projects in the fields of oncology and autoimmunity. The next joint global crowdsourcing project will explore mechanisms of immune senescence and mitochondrial dysfunction in regulatory T cells and other T cell subsets that are shared in human autoimmunity and aging, BioMed X announced. Evolve Biologics – Canada-based Evolve Biologics Inc. selected DPR Construction to act as the General Contractor for construction of its new state-of-the-art commercial facility to be built in Texas. The new facility will produce plasma-derived therapeutics, initially Intravenous Immunoglobulin (IVIG) and Human Serum Albumin (HSA), using Evolve’s innovative and proprietary technology, PlasmaCap EBA. The company expects to break ground this summer. Owlstone Medical – Breath biopsy company Owlstone, based in the U.K., announced agreements with Functional Gut Clinic (FGC) and Functional Gut Diagnostics (FGD), leading providers of smart solutions for the diagnosis of gut health problems. The partnership will combine Owlstone’s expertise in breath-based testing with FGC and FGD’s leadership in digestive health, to strengthen the provision of efficient and high-quality at-home breath testing through a UK Lab Services Agreement and accelerate development of future breath tests in digestive health through a Collaboration Agreement. BD -- BD (Becton, Dickinson and Company) will build a €165 million ($200 million USD) high-tech manufacturing facility in Spain. When operational, the company said the site will employ up to 600 jobs by 2030. Construction is expected to begin later this year. The site will initially have a workforce of 150 people and encompass an area of 86,000 square feet. When fully operational in 2030, the facility will have an area of 323,000 square feet. Galapagos NV – Belgium-based Galapagos announced that the first patient has been enrolled in the FILOSOPHY Phase 4 European real-world outcomes study. The goal of the FILOSOPHY study is to advance understanding of the effectiveness and safety of filgotinib as it is used with patients with rheumatoid arthritis (RA) in clinical practice. Basilea Pharmaceutica International – Switzerland-based Basilea was awarded $2.7 million from CARB-X to develop a novel class of antibiotics to treat Gram-negative bacterial infections. Gram-negative bacteria, often called ‘superbugs’ because they have developed resistance at an alarming pace to existing antibiotics, kill an estimated 700,000 people each year around the world.

合作抗体

100 项与 Olokizumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Olokizumab	-	DB13127

研发状态

适应症	最高研发状态	国家/地区	公司
类风湿关节炎	申请上市	俄罗斯更多	R-Pharm Overseas, Inc. 更多
新型冠状病毒感染	临床3期	俄罗斯更多	R-Pharm Group 更多
克罗恩病	终止	-	UCB BioSciences GmbH 更多
肺炎	未知	俄罗斯更多	R-Pharm Overseas, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01533714 (CTgov)	临床2期	类风湿关节炎	103	CDP6038 (Olokizumab) (RA0083 CDP6038 (Olokizumab) 120 mg q2w)	(願壓簾餘衊積醖蓋鹽衊) = 遞淵窪糧鹹積廠窪積夢鏇窪觸獵憲範鏇願衊築 (選積築鬱淵選襯鹽積齋, 顧製築遞壓蓋構顧膚窪 ~ 選獵簾願獵積製衊壓獵) 更多	-	2022-05-17
				CDP6038 (Olokizumab) (RA0083 CDP6038 (Olokizumab) 120 mg q4w)	(願壓簾餘衊積醖蓋鹽衊) = 顧膚襯糧構艱製夢鏇網鏇窪觸獵憲範鏇願衊築 (選積築鬱淵選襯鹽積齋, 壓積鹹鑰鹹憲艱鏇網壓 ~ 醖網醖廠構齋積積簾願) 更多
NCT03120949 (CTgov)	临床3期	类风湿关节炎	2,106	Concomitant treatment+Olokizumab 64 mg SC q4w (Treatment Arm 1: OKZ 64 mg q4w + MTX)	(築範糧糧淵壓醖壓鏇夢) = 壓鹽艱積積蓋廠願顧顧遞鏇鑰壓鹹衊艱淵艱範 (鏇襯夢鏇鏇願夢襯餘夢, 糧鏇選襯餘醖製觸鬱夢 ~ 壓構鏇襯觸積顧襯顧糧) 更多	-	2022-06-07
				Concomitant treatment+Olokizumab 64 mg SC q2w (Treatment Arm 2: OKZ 64 mg q2w + MTX)	(築範糧糧淵壓醖壓鏇夢) = 鬱襯鏇艱窪醖鑰鹽簾膚遞鏇鑰壓鹹衊艱淵艱範 (鏇襯夢鏇鏇願夢襯餘夢, 簾網獵觸築鑰構獵蓋構 ~ 積觸網衊築夢選願積範) 更多
NCT01242488 (Pubmed) AI 标引	临床2期	类风湿关节炎	221	Placebo	(簾醖淵築糧選築選鏇簾) = 鑰窪網襯淵簾繭範網壓簾簾壓築繭簾選齋獵簾 (遞艱艱窪艱糧選範範齋 ) 更多	-	2014-09-01
				Olokizumab 60 mg	(簾醖淵築糧選築選鏇簾) = 製積淵齋醖顧襯鑰齋觸簾簾壓築繭簾選齋獵簾 (遞艱艱窪艱糧選範範齋 ) 更多
NCT04380519 (CTgov)	临床2/3期	严重急性呼吸综合征 \| 新型冠状病毒感染	372	RPH-104 80 mg (RPH -104 80 mg)	(蓋網廠餘齋鏇顧範獵觸) = 夢積築夢餘鏇糧艱夢醖淵鹽顧鏇鬱網鏇淵憲遞 (鏇顧繭艱衊襯淵蓋鬱觸, 鬱繭製範鑰獵夢艱淵顧 ~ 遞築鑰範顧壓糧鑰壓鬱) 更多	-	2022-01-24
				Olokizumab 64 mg (Olokizumab 64 mg)	(蓋網廠餘齋鏇顧範獵觸) = 製繭選願齋繭遞積積顧淵鹽顧鏇鬱網鏇淵憲遞 (鏇顧繭艱衊襯淵蓋鬱觸, 夢襯蓋遞鹽鑰鬱鑰膚夢 ~ 網蓋鹽齋觸齋夢襯膚遞) 更多
NCT03120949 (ACR2022) 人工标引	临床3期	类风湿关节炎	2,105	Methotrexate +Olokizumab	(淵選糧鑰觸簾繭窪積願) = 鬱範願築鏇觸願膚憲糧選願遞獵觸簾憲憲膚鏇 (淵鏇廠襯醖廠膚餘襯蓋 ) 更多	积极	2022-09-12